share_log

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

6-K：諾和諾德停止Ocedurenone CLARION-CKD試驗並確認減值損失
美股SEC公告 ·  06/27 01:22

牛牛AI助理已提取核心訊息

On June 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the termination of the CLARION-CKD phase 3 trial, which was evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The decision to stop the trial came after an independent data monitoring committee concluded that the trial did not meet its primary endpoint during a prespecified interim analysis. As a result, Novo Nordisk will recognize an impairment loss of approximately DKK 5.7 billion, which is expected to negatively impact operating profit growth by about 6 percentage points for the year 2024. This financial impact is in comparison to the operating profit outlook previously communicated for the first quarter of 2024. The company, which acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023, is now evaluating the further development of ocedurenone for other indications. Novo Nordisk will disclose its financial results for the first half of 2024 and update its financial outlook for the full year on August 7, 2024.
On June 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the termination of the CLARION-CKD phase 3 trial, which was evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The decision to stop the trial came after an independent data monitoring committee concluded that the trial did not meet its primary endpoint during a prespecified interim analysis. As a result, Novo Nordisk will recognize an impairment loss of approximately DKK 5.7 billion, which is expected to negatively impact operating profit growth by about 6 percentage points for the year 2024. This financial impact is in comparison to the operating profit outlook previously communicated for the first quarter of 2024. The company, which acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023, is now evaluating the further development of ocedurenone for other indications. Novo Nordisk will disclose its financial results for the first half of 2024 and update its financial outlook for the full year on August 7, 2024.
2024年6月26日，領先的全球醫療保健公司諾和諾德公司宣佈終止CLARION-CKD 3期臨床試驗。該試驗評估了氯匹利片治療在控制不住的高血壓和晚期慢性腎臟疾病患者上的療效。在預定中期分析期間，獨立數據監測委員會得出結論，該試驗未達到首要終點。因此，諾和諾德將認定約57億丹麥克朗的減值損失，預計將對2024年的營業利潤增長產生約6個百分點的負面影響。這種財務影響與公司此前公佈的2024年第一季度營業利潤預期相比。該公司於2023年從KBP生物科技有限公司收購了氯匹利片，現在正在評估氯匹利片在其他適應症中的進一步研發。諾和諾德將於2024年8月7日披露其上半年財務業績並更新全年財務展望。
2024年6月26日，領先的全球醫療保健公司諾和諾德公司宣佈終止CLARION-CKD 3期臨床試驗。該試驗評估了氯匹利片治療在控制不住的高血壓和晚期慢性腎臟疾病患者上的療效。在預定中期分析期間，獨立數據監測委員會得出結論，該試驗未達到首要終點。因此，諾和諾德將認定約57億丹麥克朗的減值損失，預計將對2024年的營業利潤增長產生約6個百分點的負面影響。這種財務影響與公司此前公佈的2024年第一季度營業利潤預期相比。該公司於2023年從KBP生物科技有限公司收購了氯匹利片，現在正在評估氯匹利片在其他適應症中的進一步研發。諾和諾德將於2024年8月7日披露其上半年財務業績並更新全年財務展望。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間